Prospective evaluation of fluorouracil chemotherapy based on the genetic makeup of colorectal cancer

Gut

Volumn 55, Issue 6, 2006, Pages 759-761

  Carethers, J M ^a  

^a VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA POLYMERASE; FLUOROURACIL; LEVAMISOLE; MUCIN; PROTEIN MLH1;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CELL DEATH; CLINICAL TRIAL; COLON CARCINOGENESIS; COLORECTAL CANCER; FAMILIAL CANCER; GENETIC DISORDER; GENETIC TRAIT; GENOME; HUMAN; METASTASIS; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; NOTE; PALLIATIVE THERAPY; PRIORITY JOURNAL; PROGNOSIS; TUMOR GROWTH;

ANTIMETABOLITES, ANTINEOPLASTIC; BASE PAIR MISMATCH; COLORECTAL NEOPLASMS; DNA REPAIR; DNA, NEOPLASM; FLUOROURACIL; HUMANS; PATIENT SELECTION; TREATMENT OUTCOME;

EID: 33646795646     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2005.085274     Document Type: Note

References (27)

1. Boland CR, Sinicrope FA, Brenner DE, et al. Colorectal cancer prevention and treatment. Gastroenterology 2000;118:S115-28.
2. Laurie JA, Moertel CG, Fleming TR, et al. Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. The North Central Cancer Treatment Group and the Mayo Clinic. J Clin Oncol 1989;7:1447-56.
3. Moertel CG, Fleming TR, Macdonald JS, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990;322:352-8.
4. Moertel CG, Fleming TR, Macdonald JS, et al. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med 1995;122:321-6.
5. Carethers JM. Biology of colorectal carcinoma. In: Rustgi A, Crawford J, eds. Gastrointestinal cancers: biology and clinical management, 2nd edn. Philadelphia: WB Sounders, 2003:407-19
6. Carethers JM, Hawn MT, Chauhan DP, et al. Competency in mismatch repair prohibits clonal expansion of cancer cells treated with N-methyl-N′-nitro- N-nitrosoguanidine. J Clin Invest 1996;98:199-206.
7. Hawn MT, Umar A, Carethers JM, et al. Evidence for a connection between the mismatch repair system and the G2 cell cycle checkpoint. Cancer Res 1995;55:3721-5.
8. Carethers JM, Chauhan DP, Fink D, et al. Mismatch repair proficiency and in vitro response to 5-fluorouracil. Gastroenterology 1999;117:123-31.
9. Papouli E, Cejka P, Jiricny J. Dependence of the cytotoxicity of DNA-damaging agents on the mismatch repair status of human cells. Cancer Res 2004;64:3391-4.
10. Jung B, Doctolero RT, Tajima A, et al. Loss of activin receptor type 2 protein expression in microsatellite unstable colon cancers. Gastroenterology 2004;126:654-9.
11. Tajima A, Hess MT, Cabrera BL, et al. The mismatch repair complex hMutS alpha recognizes 5-fluorouracil-modified DNA: implications for chemosensitivity and resistance. Gastroenterology 2004;127:1678-84.
12. Meyers M, Wagner MW, Mazurek A, et al. DNA mismatch repair-dependent response to fluoropyrimidine-generated damage. J Biol Chem 2005;280:5516-26.
13. Gryfe R, Kim H, Hsieh ET, et al. Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N Engl J Med 2000;342:69-77.
14. Guidoboni M, Gafa R, Viel A, et al. Microsatellite instability and high content of activated cytotoxic lymphocytes identify colon cancer patients with a favorable prognosis. Am J Pathol 2001;159:297-304.
15. Samowitz WS, Curtin K, Ma KN, et al. Microsatellite instability in sporadic colon cancer is associated with an improved prognosis at the population level. Cancer Epidemiol Biomarkers Prev 2001;10:917-23.
16. Popat S, Hubner R, Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol 2005;23:609-18.
17. Hemminki A, Mecklin JP, Jarvinen H, et al. Microsatellite instability is a favorable prognostic indicator in patients with colorectal cancer receiving chemotherapy. Gastroenterology 2000;119:921-8.
18. Elsaleh H, Powell B, Soontrapornchai P, et al. p53 gene mutation, microsatellite instability and adjuvant chemotherapy: impact on survival of 388 patients with Dukes' C colon carcinoma. Oncology 2000;58:52-9.
19. Elsaleh H, Joseph D, Grieu F, et al. Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer. Lancet 2000;355:1745-50.
20. Carethers JM, Smith EJ, Behling CA, et al. Use of 5-fluorouracil and survival in patients with microsatellite-unstable colorectal cancer. Gastroenterology 2004;126:394-401.
21. Ribic CM, Sargent DJ, Moore MJ, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 2003;349:247-57.
22. de Vos tot Nedervee Cappel WH, Neulenbeld HJ, Keibeuker JH, et al. Survival after adjuvant 5-FU treatment for stage III coon cancer in hereditary nonpolyposis colorectal cancer. In J Cancer 2004;109:468-71.
23. Jover R, Zapater P, Castells A, et al. Mismatch repair status in the prediction of benefit from adjuvant fluorouracil chemotherapy in colorectal cancer. Gut 2006;55:848-55.
24. Southey MC, Jenkins AM, Mead L, et al. Use of molecular tumor characteristics to prioritize mismatch repair gene testing in early-onset colorectal cancer. J Clin Oncol 2005;23:6524-32.
25. Hampel H, Frankel WL, Martin E, et al. Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med 2005;352:1851-60.
26. Fink D, Nebel S, Aebi S, et al. The role of DNA mismatch repair in platinum drug resistance. Cancer Res 1996;56:4881-6.
27. Fallik D, Borrini F, Boige V, et al. Microsatellite instability is a predictive factor of the tumor response to irinotecan in patients with advanced colorectal cancer. Cancer Res 2003;63:5738-44.